Literature DB >> 33036822

Clinical phenotypes of spinal muscular atrophy patients with hybrid SMN gene.

Emma Tabe Eko Niba1, Hisahide Nishio2, Yogik Onky Silvana Wijaya3, Poh San Lai4, Takenori Tozawa5, Tomohiro Chiyonobu6, Misaki Yamadera7, Kentaro Okamoto8, Hiroyuki Awano9, Yasuhiro Takeshima10, Toshio Saito11, Masakazu Shinohara12.   

Abstract

BACKGROUND: Spinal muscular atrophy (SMA) is a neuromuscular disease caused by homozygous deletion of SMN1 exons 7 and 8. However, exon 8 is retained in some cases, where SMN2 exon 7 recombines with SMN1 exon 8, forming a hybrid SMN gene. It remains unknown how the hybrid SMN gene contribute to the SMA phenotype.
METHOD: We analyzed 515 patients with clinical suspicion for SMA. SMN1 exons 7 and 8 deletion was detected by PCR followed by enzyme digestion. Hybrid SMN genes were further analyzed by nucleotide sequencing. SMN2 copy number was determined by real-time PCR.
RESULTS: SMN1 exon 7 was deleted in 228 out of 515 patients, and SMN1 exon 8 was also deleted in 204 out of the 228 patients. The remaining 24 patients were judged to carry a hybrid SMN gene. In the patients with SMN1 exon 7 deletion, the frequency of the severe phenotype was significantly lower in the patients with hybrid SMN gene than in the patients without hybrid SMN gene. However, as for the distribution of SMN2 exon 7 copy number among the clinical phenotypes, there was no significant difference between both groups of SMA patients with or without hybrid SMN gene.
CONCLUSION: Hybrid SMN genes are not rare in Japanese SMA patients, and it appears to be associated with a less severe phenotype. The phenotype of patients with hybrid SMN gene was determined by the copy number of SMN2 exon 7, as similarly for the patients without hybrid SMN gene.
Copyright © 2020 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gene conversion; Hybrid SMN gene; SMN1; SMN2; Spinal muscular atrophy

Year:  2020        PMID: 33036822     DOI: 10.1016/j.braindev.2020.09.005

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

1.  Newborn screening for spinal muscular atrophy in Japan: One year of experience.

Authors:  Takaaki Sawada; Jun Kido; Keishin Sugawara; Shinichiro Yoshida; Shiro Ozasa; Keiko Nomura; Kentaro Okada; Natsumi Fujiyama; Kimitoshi Nakamura
Journal:  Mol Genet Metab Rep       Date:  2022-08-02

Review 2.  Recommendations for Interpreting and Reporting Silent Carrier and Disease-Modifying Variants in SMA Testing Workflows.

Authors:  John N Milligan; Laura Blasco-Pérez; Mar Costa-Roger; Marta Codina-Solà; Eduardo F Tizzano
Journal:  Genes (Basel)       Date:  2022-09-15       Impact factor: 4.141

3.  Multisite Evaluation and Validation of a Sensitive Diagnostic and Screening System for Spinal Muscular Atrophy that Reports SMN1 and SMN2 Copy Number, along with Disease Modifier and Gene Duplication Variants.

Authors:  John N Milligan; Jessica L Larson; Stela Filipovic-Sadic; Walairat Laosinchai-Wolf; Ya-Wen Huang; Tsang-Ming Ko; Kristin M Abbott; Henny H Lemmink; Minna Toivonen; Johanna Schleutker; Caren Gentile; Vivianna M Van Deerlin; Huiping Zhu; Gary J Latham
Journal:  J Mol Diagn       Date:  2021-03-30       Impact factor: 5.341

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.